Information Provided By:
Fly News Breaks for June 29, 2018
ARWR
Jun 29, 2018 | 14:11 EDT
Piper Jaffray analyst Edward Tenthoff noted that Arrowhead presented preliminary Phase 1 data on ARO-AAT that he was encouraged by and he anticipates the company could begin a robust Phase 2 study in AAT liver disease patients next year. Given his increased estimates for the value of ARO-AAT and ARO-HBV, Tenthoff raised his price target on Arrowhead shares to $17 and reiterated an Overweight rating on the stock.
News For ARWR From the Last 2 Days
There are no results for your query ARWR